KESHEA ROUSE: Open Payments
NPI 1467019364 · ENGLEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$410 in 17 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $410
Food & beverage: $410
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $61 |
| Almatica Pharma LLC | 2 | $61 |
| ABBVIE INC. | 2 | $54 |
| Alkermes, Inc. | 2 | $52 |
| Lilly USA, LLC | 2 | $46 |
| Lundbeck LLC | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $27 |
Products named: INGREZZA, LOREEV XR, VRAYLAR, ARISTADA, ZEPBOUND, REXULTI, UZEDY, AUSTEDO XR.
Industry payments across CO — which companies pay providers there.
